Table of Content


Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360? synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of eosinophilic esophagitis
3.2.1.2 Advancement in diagnostic techniques
3.2.1.3 Development of target drug therapies
3.2.1.4 Increasing healthcare investment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Competition from generic drugs
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 Biologics
5.3 Corticosteroids
5.4 Proton pump inhibitors
5.5 Immunomodulators
5.6 Other drug class
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Topical
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 Pediatric
7.3 Adult
7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Allakos
10.2 Arena Pharmaceuticals
10.3 AstraZeneca
10.4 Cipla
10.5 Ellodi Pharmaceuticals
10.6 EsoCap
10.7 GlaxoSmithKline
10.8 Revolo Biotherapeutics
10.9 Sanofi
10.10 Sun Pharmaceutical
10.11 Takeda Pharmaceutical Company
10.12 Teva Pharmaceutical